Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P36021

UPID:
MOT8_HUMAN

ALTERNATIVE NAMES:
Monocarboxylate transporter 7; Solute carrier family 16 member 2; X-linked PEST-containing transporter

ALTERNATIVE UPACC:
P36021; Q7Z797

BACKGROUND:
The Monocarboxylate transporter 8, alternatively known as X-linked PEST-containing transporter, is essential for the transmembrane transport of thyroid hormones such as T3 and T4. Its role extends to the blood-brain barrier, where it mediates the transport of T3, a crucial hormone for brain development and function. This protein's activity is vital for the proper distribution of thyroid hormones in various tissues.

THERAPEUTIC SIGNIFICANCE:
Deficiency in Monocarboxylate transporter 8 leads to a complex neurological and endocrinological condition, underscoring the transporter's importance in human health. The link between MCT8 and Monocarboxylate transporter 8 deficiency offers a promising avenue for therapeutic intervention, aiming to correct or mitigate the effects of impaired thyroid hormone transport.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.